# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

## **SCHEDULE 14A**

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant  $\boxtimes$ 

Filed by a Party other than the Registrant  $\Box$ 

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- □ Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Pursuant to § 240.14a-12

# **ZIOPHARM Oncology, Inc.**

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☑ No fee required.
- $\Box$  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  - (2) Aggregate number of securities to which transaction applies:
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  - (4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

□ Fee paid previously with preliminary materials:

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

#### \*\*\* Exercise Your *Right* to Vote \*\*\* Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 19, 2013

ZIOPHARM ONCOLOGY, INC.

ZIOPHARN ONCOLOGY, INC. AITN: CORPORATE SECRETARY ONE FIRST AVENUE, PARRIS BLDG #34 NAVY YARD PLAZA POSTON DR. 02120 Meeting Type: Annual Meeting For holders as of: April 22, 2013 Date: June 19, 2013 Time: 11:00 AM EST Location: One First Avenue Parris Building 34 Navy Yard Plaza Boston, Massachusetts 02129

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxywote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

### — Before You Vote —

How to Access the Proxy Materials

## How To Vote —

Please Choose One of the Following Voting Methods

**Vote In Person:** Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

**Vote By Internet:** To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow  $\rightarrow$  [XXXX XXXX XXXX] available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

	Voting ite	ems										
	Board of Directors re the following:	commende	s you vote									
	Election of Directors Nominees											
	Jonathan Lewis		Murray Brennan	03	James A.	Cannon	04	Wyche F	owler, Jr.	05	Randal J. Kir	ĸ
06	Fimothy McInerney	07	Michael Weiser									
-	Board of Directors re	comende	way yote EOP propr	sale 2 a	and 3							

2. To ratify the appointment of McGladrey LLP as our independent registered public accounting firm for 2013; and

 To approve, on an advisory basis, the compensation of our named executive officers as identified in the proxy statement for the annual meeting.

NOTE: To transact any other business as may properly come before the meeting or any adjournments or postponements thereof.

0000178406\_4 R1.0.0.51160